1Q Revenues: $716 million, (+17%)
1Q Earnings: $132 million (+7%)
Comments: Growth in the quarter was driven by Avonex sales, up 14% to $449 million, and Rituxan revenues from the joint business arrangement with Genentech, up 13% to $207 million. Global in-market net sales of Tysabri in the quarter were $48 million, of which Biogen recognized $30 million based on its collaboration with Elan. R&D expenses were $191.4 million, up 31%. In the quarter, the company completed its acquisition of Syntonix Pharmaceuticals, which included an in-process R&D charge of $18 million.